US Patent

US12257252 — Compositions and methods for increasing tetrahydrobiopterin plasma exposure

Method of Use · Assigned to PTC Therapeutics MP Inc · Expires 2042-03-06 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions containing sepiapterin and methods for treating BH4-related disorders by increasing tetrahydrobiopterin plasma exposure.

USPTO Abstract

The present invention features compositions including sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for the treatment of BH4-related disorders. In some embodiments, these compositions and methods result in an increase in plasma exposure of BH4.

Drugs covered by this patent

Sephience (SEPIAPTERIN) · Ptc Therap

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4250`	—	Sephience
`U-4250`	—	Sephience

Patent Metadata

Patent number: US12257252
Jurisdiction: US
Classification: Method of Use
Expires: 2042-03-06
Drug substance claim: No
Drug product claim: No
Assignee: PTC Therapeutics MP Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.